Brought to you by 
Fulcrum gets global rights to GSK's losmapimod for muscular dystrophy
03 Sep 2019
Executive Summary
GlaxoSmithKline PLC licensed Fulcrum Therapeutics Inc. exclusive worldwide rights to develop and commercialize losmapimod for facioscapulohumeral muscular dystrophy (FSHD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fulcrum gets global rights to GSK's losmapimod for muscular dystrophy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice